Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multicenter, multiple dose, dose escalation study of the
safety, PK, PD, and anti-tumor activity of IDE397 as a single agent in adult patients with
selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to
standard of care therapy or for whom no curative therapy is available.